HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, February 11 Agendia, a world leader in molecular cancer diagnostics,today announced the appointment of Alan B. Carter as the company's new VicePresident of Global Business Development.
"As we continue to grow as a global company, Alan's appointment furthersone of our primary aims," commented Dr. Bernhard Sixt, Ph.D., President andChief Executive Officer. "His extensive business development expertise willstrengthen our ongoing programs and pipeline projects and also allows us tocapitalize on our genomics platform in close collaboration with biotechnologyand pharmaceutical partners. With Alan's involvement, Agendia will continueto play a central role in making targeted therapies one of the cornerstonesof personalized medicine."
Mr. Carter brings 25 years of business development, sales and marketingexperience from a number of top tier life sciences companies such asBioTrove, Celera, Applied Biosystems and Perkin Elmer. At Agendia, Mr. Carterwill assume responsibility for strategic business opportunities to build onthe current success of Agendia's molecular diagnostics portfolio. Thisproducts suite includes MammaPrint(R), the only FDA approved test for rapidlyand accurately diagnosing therapeutic options for breast cancer patients.Additionally, he will play an important role in forging Agendia's strategicalliances with pharmaceutical and biotech companies to accelerate the use ofmolecular diagnostics in drug development, companion diagnostics and safetytesting programs.
Agendia is at the forefront of the personalized medicine revolution,striving to bring more effective, individualized treatments within reach ofpatients. Building on a cutting edge genomics platform for tumor geneexpression profiling, the company's tests aim to help physicians moreaccurately tailor cancer treatments. The company markets four products, withseveral new genomic tests under development. In addition, Agendiacollaborates with pharmaceutical companies to develop highly effectivepersonalized drugs in the area of oncology. Agendia was awarded the 2008North American Oncology Clinical Diagnostics Healthcare Innovation Award byFrost & Sullivan. Agendia is based in Huntington Beach, California, and inAmsterdam, The Netherlands.
For more information please visit http://www.agendia.com.
SOURCE Agendia B.V.